Novel Forms of [R-(R*,R*)]-2-(4-Fluorophenyl)-Beta, Gamma-Dihydroxy-5-(1-Methylethyl)-3-Phenyl-4-[(Phenylamino)carbonyl]-1H-Pyrrole-1-Heptanoic Acid Calcium Salt (2:1)
Novel forms of [R-(R*,R*)]- 2 -( 4 -fluorophenyl)-β,δ-dihydroxy- 5 -( 1 -methylethyl)- 3 -phenyl- 4 -[(phenylamino)carbonyl]- 1 H-pyrrole- 1 -heptatonic acid hemi calcium salt designated Form XX, Form XXI, Form XXII, Form XXIII, Form XXIV, Form XXV, Form XXVI, Form XXVII, Form XXVIII, Form XXIX, and Form XXX, characterized by their X-ray powder diffraction, solid-state NMR, and/or Raman spectroscopy are described as well as methods for the preparation and pharmaceutical composition of the same, which are useful as agents for treating hyperlipidemia, hypercholesterolemia, osteoporosis, benign prostatic hyperplasia (BPH) and Alzheimer's disease.
1 . (canceled)
2 . (canceled)
3 . (canceled)
4 . A Form XXIV atorvastatin calcium having an X-ray powder diffraction containing the following 2θ values measured using CuK a radiation: 2.9, 7.4, 7.8, 8.7, 9.5, 10.0, 12.2, 18.0, 18.6, 19.0, and 22.7.
5 . (canceled)
6 . (canceled)
7 . (canceled)
8 . A Form XXVIII atorvastatin calcium having an X-ray powder diffraction containing the following 2θ values measured using CuK a radiation: 7.6, 9.5, 12.2, 16.5, 17.0, 18.0, 20.5, 21.5, and 22.3.
9 . (canceled)
10 . A Form XXX atorvastatin calcium having an X-ray powder diffraction containing the following 2θ values measured using CuK a radiation: 3.1, 9.0, 9.7, 12.0, 16.5, 17.0, 20.9, 21.6, 22.5, and 24.3.
11 . (canceled)
12 . (canceled)
13 . (canceled)
14 . A Form XXVIII atorvastatin calcium having an X-ray powder diffraction containing the following 2θ values measured using CuK a radiation: 7.6, 9.5, 20.5, and 22.3, and a solid state 19 F nuclear magnetic resonance having the following chemical shifts expressed in parts per million: −116.4, −117.1, and −119.2.
15 . A Form XXX atorvastatin calcium having an X-ray powder diffraction containing the following 2θ values measured using CuK a radiation: 3.1, 9.0, and 21.6, and a solid state 19 F nuclear magnetic resonance having the following chemical shifts expressed in parts per million: −116.7 and −118.6.